Core Viewpoint - The article discusses the ongoing efforts by the Trump administration to lower drug prices in the U.S., highlighting the strong pricing power of pharmaceutical companies and the complexities of the healthcare payment system, which includes private insurance and pharmacy benefit managers (PBMs) [2][35]. Summary by Sections U.S. Healthcare System Overview - The U.S. healthcare system is characterized by high medical service costs and low insurance coverage rates compared to other developed countries, with total healthcare spending reaching approximately $4.9 trillion in 2023, accounting for 17.6% of GDP [4][5]. - From 1960 to 2023, per capita national health expenditure in the U.S. increased from $146 to $14,570, a 99-fold increase with a compound annual growth rate of 7.6% [4]. Insurance Coverage and Efficiency - The U.S. insurance coverage rate is relatively low among developed nations, with 2023 coverage at 92.4%, lower than most OECD countries [9]. - The efficiency of healthcare services is also a concern, with the U.S. showing only an 8.8% decrease in all-cause mortality from 1999 to 2022, compared to a 25.9% decrease in the UK during the same period [7]. Medicare and Medicaid - Medicare, the primary public insurance program, covers approximately 65 million elderly and disabled individuals, while Medicaid covers about 91.7 million low-income individuals, with a compound annual growth rate of 7.0% in spending from 2013 to 2023 [18][19]. - Private insurance dominates the U.S. healthcare system, covering about 207 million people, or 62% of the population, with employer-sponsored plans being the most common [19]. PBM Role and Pricing Mechanisms - Pharmacy Benefit Managers (PBMs) play a crucial role in the drug supply chain, managing drug formularies and negotiating prices, but their profit mechanisms, including rebate retention and price differentials, contribute to high drug prices [26][28]. - The consolidation of PBMs has raised concerns about their influence on drug pricing and transparency, prompting regulatory scrutiny at both state and federal levels [30]. Drug Pricing Reforms - The Trump administration has initiated several measures to reduce drug prices, including the Inflation Reduction Act, which allows for direct price negotiations for Medicare-covered drugs [33][35]. - The administration's efforts include setting price caps on insulin and negotiating discounts with pharmaceutical companies, with significant reductions observed in negotiated drug prices [33][39]. Pharmaceutical Pricing Trends - According to ICER, the median list price of new drugs is projected to increase by 24% and the net price by 51% from 2022 to 2024, indicating the continued strong pricing power of pharmaceutical companies [2][40]. - The article concludes that the interplay of the healthcare payment system, PBM profit mechanisms, and pharmaceutical pricing power complicates the effectiveness of drug price reform initiatives [39][40].

Core Viewpoint - Amgen Inc. is recognized as one of the 15 best S&P 500 dividend stocks to buy in 2026, indicating strong investor interest and confidence in its future performance [1] Group 1: Analyst Ratings and Market Outlook - Bernstein downgraded Amgen from Outperform to Market Perform, maintaining a price target of $335, citing 2026 as a "waiting year" for its drug MariTide [2] - Concerns were raised regarding potential risks to Amgen's Repatha due to Merck's pricing strategies, along with uncertainties surrounding the significance of Lp(a) outcomes, with more clarity expected from Novartis' pelicarsen data [2] Group 2: Acquisition and Pipeline Development - Amgen announced the acquisition of Dark Blue Therapeutics Ltd. for up to $840 million, aimed at enhancing its oncology pipeline [3] - The acquisition focuses on a small molecule that targets proteins MLLT1/3, which are implicated in acute myeloid leukemia (AML), showing promising preclinical results that suggest a unique mechanism of action compared to existing treatments [4] - Amgen plans to integrate Dark Blue into its research organization to bolster early-stage oncology discovery efforts [5]

Group 1 - UBS raised the target price for Amgen from $380 to $390 while maintaining a "Buy" rating [1]

Core Insights - The article discusses the 15 best S&P 500 dividend stocks to consider for investment in 2026, emphasizing the stability that dividend stocks can provide during market downturns [1] Dividend and Buyback Strategy - Dan Lefkovitz from Morningstar Indexes suggests that combining dividend-paying stocks with companies that actively buy back shares can yield better returns compared to a high-dividend-only strategy [2] - An index that includes both dividends and buybacks has outperformed a high-dividend-only index over the past three years, although it still lags behind the overall US market [2] Cash Return to Shareholders - The article highlights the difference in how companies return cash to shareholders, noting that dividends are a long-term commitment while buybacks are more flexible and often increase when management perceives the stock as undervalued [3] - Large technology companies have been leading in buyback activities, while dividend payments are primarily concentrated in sectors like financials, utilities, energy, and consumer staples [3] International Dividend Yields - Income-focused investors are encouraged to look beyond the US, as domestic dividend yields have decreased to approximately 1.1%, while some European regions offer yields above 3% [4] - Caution is advised against chasing high yields, as unusually high payouts may indicate underlying business stress and potential future dividend cuts [4] Methodology for Stock Selection - The selection process for the 15 best dividend stocks involved screening S&P 500 companies with a market cap of at least $10 billion, focusing on those with stable dividends and yields around 2% as of January 21 [6] - The final list was based on popularity among hedge funds, utilizing data from Insider Monkey's Q3 2025 database [6][7] Company-Specific Insights - **Verizon Communications Inc. (NYSE:VZ)**: - Holds a dividend yield of 7.06% as of January 21, with 60 hedge fund holders [8] - Bernstein has cut its price target for Verizon to $44, citing increased competition in the telecom industry [8] - Verizon's $20 billion acquisition of Frontier Communications was approved, with commitments to expand fiber internet and wireless coverage in California [9] - **Amgen Inc. (NASDAQ:AMGN)**: - Has a dividend yield of 3.05% as of January 21, with 62 hedge fund holders [11] - Bernstein downgraded Amgen to Market Perform, indicating 2026 may be a waiting year for its product MariTide [11] - Amgen announced the acquisition of Dark Blue Therapeutics for up to $840 million, enhancing its oncology pipeline [12][13]

*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet. IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC. About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Checkup Stock Quotes Stock Market Today The Big Picture My Stock ...

Executive Appointments - Michelin appointed Bénédicte de Bonnechose as its new finance chief, effective June 1, succeeding Yves Chapot [2] - Ember LifeSciences hired Ann Hyllengren as chief financial officer, previously a senior director at Amgen [3] - AuditBoard named Hugo Doetsch as CFO, who previously served as CFO at Symplr and played a key role in Ping Identity's IPO [4] - CAE announced Ryan McLeod as its next CFO, effective February 23, replacing interim CFO Constantino Malatesta [5] Career Backgrounds - Bénédicte de Bonnechose joined Michelin in April 2019 and has experience in financial roles at Lafarge Group [2] - Ann Hyllengren has 18 years of experience at Amgen, including senior finance leadership roles and oversight of the Amgen Foundation [3] - Hugo Doetsch has held senior leadership roles at multiple companies, including CFO positions at Symplr and NetDocuments [4] - Ryan McLeod has been CFO at ATS since 2020 and has prior experience at CIBC Mellon and EY [5]

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - The newsletter is led by a biotech consultant with over 5 years of experience, who has compiled detailed reports on more than 1,000 companies [1] - The investing group, Haggerston BioHealth, caters to both novice and experienced investors, providing insights on product sales, forecasts for major pharmaceutical companies, and various financial analyses [1]

Core Viewpoint - The article promotes a weekly newsletter focused on biotech, pharma, and healthcare stocks, highlighting key trends and catalysts that influence market valuations [1]. Group 1 - The newsletter is led by a biotech consultant with over 5 years of experience covering the industry and has compiled detailed reports on more than 1,000 companies [1]. - The investing group, Haggerston BioHealth, caters to both novice and experienced biotech investors, providing insights on catalysts, buy and sell ratings, and forecasts for major pharmaceutical companies [1]. - The group offers integrated financial statements, discounted cash flow analysis, and market-by-market analysis to aid investors in making informed decisions [1].

Group 1: Collaboration and Strategy - Amgen Inc. is collaborating with Ro, a telehealth firm, to investigate barriers patients face in accessing obesity treatments, particularly GLP-1 drugs [2][3] - The collaboration aims to leverage data from Ro's platform to assess insurance coverage, prior authorization requirements, and improve patient access to GLP-1 therapies [3] - Amgen expects the observational research from this collaboration to aid in therapy development and innovate care delivery [3] Group 2: Acquisition and Oncology Focus - Amgen acquired Dark Blue Therapeutics for up to $840 million, a UK-based biotech company focused on small molecule protein degraders for acute myeloid leukemia [4] - The acquisition supports Amgen's strategy to enhance early oncology discovery and commitment to novel therapeutic mechanisms [4] Group 3: Company Overview - Amgen Inc. is a biotechnology company that develops, manufactures, and markets human therapeutics, founded in 1980 and headquartered in Thousand Oaks, CA [5]

Core Viewpoint - Amgen Inc. is facing a potential increase in stock price according to Bernstein's target, but legal challenges may impact its performance and reputation [1][4][5]. Group 1: Stock Performance - Bernstein has set a price target of $335 for Amgen, suggesting a potential increase of about 1.38% from the current stock price of $330.06 [1][6]. - The stock has fluctuated today, with a low of $321.71 and a high of $330.83, reflecting its volatility [2]. - Over the past year, Amgen's stock has reached a high of $346.38 and a low of $261.43, indicating significant market fluctuations [2][6]. Group 2: Market Capitalization and Trading Activity - Amgen's market capitalization is approximately $177.73 billion, underscoring its substantial presence in the pharmaceutical industry [3]. - The trading volume for the day is 971,158 shares on the NASDAQ exchange, indicating active investor interest [3]. Group 3: Legal Challenges - Amgen is facing a lawsuit from Sagebrush Health Services, alleging unlawful termination of discounted drug sales, which could affect over 10,000 patients in Nevada [4]. - This legal issue may impact Amgen's reputation and financial performance, necessitating close monitoring by investors [5][6].